Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBIT (2017 - 2025)

Historic EBIT for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$40.3 million.

  • Dianthus Therapeutics' EBIT fell 3474.25% to -$40.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.3 million, marking a year-over-year decrease of 6924.15%. This contributed to the annual value of -$101.9 million for FY2024, which is 11145.02% down from last year.
  • Per Dianthus Therapeutics' latest filing, its EBIT stood at -$40.3 million for Q3 2025, which was down 3474.25% from -$34.9 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' EBIT ranged from a high of -$7.7 million in Q1 2023 and a low of -$40.3 million during Q3 2025
  • Its 4-year average for EBIT is -$21.3 million, with a median of -$17.8 million in 2024.
  • In the last 5 years, Dianthus Therapeutics' EBIT crashed by 2116.34% in 2023 and then crashed by 14634.15% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' EBIT (Quarter) stood at -$10.7 million in 2022, then dropped by 21.16% to -$13.0 million in 2023, then tumbled by 146.34% to -$31.9 million in 2024, then fell by 26.23% to -$40.3 million in 2025.
  • Its EBIT was -$40.3 million in Q3 2025, compared to -$34.9 million in Q2 2025 and -$33.2 million in Q1 2025.